home / stock / mreo / mreo news

MREO News and Press, Mereo BioPharma Group From 07/08/21

Stock Information
Company Name: Mereo BioPharma Group
Stock Symbol: MREO
Market: NASDAQ
Website: mereobiopharma.com
Menu
MREO MREO Quote MREO Short MREO News MREO Articles MREO Message Board
Get MREO Alerts

News, Short Squeeze, Breakout and More Instantly...
MREO - Tracking Baker Brothers Portfolio - Q1 2021 Update

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
MREO - Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

MREO - Idera Pharmaceuticals, Beyond Air leads healthcare gainers; Mereo BioPharma, Portage Biotech among major losers

Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, ...

MREO - Healthcare names lead premarket gainers

Enochian Biosciences (ENOB) +143% on FDA acceptance of pre-IND request for potential HIV cure.MediaCo Holding (MDIA) +63%.iTeos Therapeutics (ITOS) +52%.Entasis Therapeutics Holdings (ETTX) +25%.Orphazyme A/S (ORPH) +23%.Luokung Technology (LKCO) +22%.Mereo BioPharma Group plc (MREO) +17...
MREO - Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

LONDON and REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced positive data from an interim...

MREO - Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, ...

MREO - Esperion sinks after Stifel downgrade, Community Health adds another bull; in today's healthcare analyst action

Esperion sheds nearly a third on Stifel cut Esperion Therapeutics (ESPR) has lost ~32.8% in the early hours after Stifel downgraded the stock to hold from buy noting “we don't think this story gets any better soon.”Esperion’s Q1 2021 financials came be...
MREO - ATVI, TEVA, AYX and LYFT among notable premarket gainers

Chiasma (CHMA) +39% on Q1 results.Athenex (ATNX) +31% on Kuur Therapeutics acquisition.Ault Global Holdings (DPW) +30% on preliminary Q1 results.iBio (IBIO) +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation (BGFV) +22% on Q1 results.DAVIDsTEA...

MREO - Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021

LONDON and REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D...

MREO - Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Mereo BioPharma (MREO) announces a partnership with Cancer Focus Fund to evaluate its lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer.The partnership will support a Phase 1b/2 clinical study of etigilimab in combination with an anti-PD-1...
Previous 10 Next 10